Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)

• Main Authors: Diego Orsini (Author), Giacomo Caldarola (Author), Annunziata Dattola (Author), Elena Campione (Author), Nicoletta Bernardini (Author), Pasquale Frascione (Author), Clara De Simone (Author), Antonio G. Richetta (Author), Marco Galluzzo (Author), Nevena Skroza (Author), Chiara Assorgi (Author), Emanuele Amore (Author), Gennaro M. Falco (Author), Ruslana Gaeta Shumak (Author), Fabio Artosi (Author), Giulia Maretti (Author), Concetta Potenza (Author), Luca Bianchi (Author), Giovanni Pellacani (Author), Ketty Peris (Author), Claudio Bonifati (Author), Dario Graceffa (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Purpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insufficientl...